María Elena Cabrera

María Elena Cabrera

Auto-generated profile, based on publicly available information

María Elena Cabrera

Hematology Department, Hospital del Salvador, University of Chile

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in JCO Global Oncology
Verified
Journal Article
Open access
LMLuis Malpica
Luis Malpica
DEDaniel J. Enriquez
Daniel J. Enriquez
DCDenisse A. Castro
Denisse A. Castro
CPCamila Peña
Camila Peña
HIHenry Idrobo
Henry Idrobo
BBBrady E. Beltran
Brady E. Beltran
PURPOSE: Adult T-cell leukemia/lymphoma (ATLL) is an aggressive disease caused by the human T-cell leukemia virus type 1. Real-world data of ATLL in Latin America are lacking. PATIENTS AND METHODS: We analyzed patients with ATLL (acute, lymphomatous, chronic, and smoldering) encountered in 11 Latin American countries between 1995 and 2019. Treatment response was assessed according to the 2009 consensus report. Survival curves were estimated using the Kaplan-Meier method and log-rank test. RESULTS: We identified 253 patients; 226 (lymphomatous: n = 122, acute: n = 73, chronic: n = 26, and smoldering: n = 5) had sufficient data for analysis (median age 57 years). Most patients with ATLL were from Peru (63%), Chile (17%), Argentina (8%), and Colombia (7%). Hypercalcemia was positively associated with acute type (57% v lymphomatous 27%, P = .014). The median survival times (months) were 4.3, 7.9, 21.1, and not reached for acute, lymphomatous, chronic, and smoldering forms, with 4-year survival rates of 8%, 22%, 40%, and 80%, respectively. First-line zidovudine (AZT)-interferon alfa (IFN) resulted in an overall response rate of 63% (complete response [CR] 24%) for acute. First-line chemotherapy yielded an overall response rate of 41% (CR 29%) for lymphomatous. CR rate was 42% for etoposide, cyclophosphamide, vincristine, doxorubicin, and prednisone versus 12% for cyclophosphamide, vincristine, doxorubicin, and prednisone–like regimen ( P < .001). Progression-free survival at 1 year for acute type patients treated with AZT-IFN was 67%, whereas 2-year progression-free survival in lymphomatous type patients who achieved CR after chemotherapy was 77%. CONCLUSION: This study confirms Latin American ATLL presents at a younger age and has a high incidence of lymphomatous type, low incidence of indolent subtypes, and worse survival rates as compared with Japanese patients. In aggressive ATLL, chemotherapy remains the preferred choice for lymphomatous favoring etoposide-based regimen (etoposide, cyclophosphamide, vincristine, doxorubicin, and prednisone), whereas AZT-IFN remains a good first-line option for acute subtype.

31 January 2025 in Blood Advances
Verified
Journal Article
Open access
JHJessy Xinyi Han
Jessy Xinyi Han
MKMin Jung Koh
Min Jung Koh
LBLeora Boussi
Leora Boussi
MSMark Sorial
Mark Sorial
SMSean M McCabe
Sean M McCabe
SJSalvia Jain
Salvia Jain
Variances in global access to drugs and treatment practices make it challenging to understand the benefit of contemporary therapies in patients with relapsed and refractory (R/R) mature T-cell and natural killer–cell lymphomas (MTCL and MNKCL). We conducted an international retrospective cohort study of 925 patients with R/R MTCL and MNKCL. In peripheral T-cell lymphoma–not otherwise specified and anaplastic lymphoma kinase–negative anaplastic large cell lymphoma (ALK– ALCL), patients with relapsed lymphoma demonstrated a superior median overall survival (OS) relative to refractory from the time of second-line treatment. We identified several independent predictors of OS for R/R lymphoma including age >60 years, primary refractory disease, histological subtype other than angioimmunoblastic T-cell lymphoma (AITL), extranodal sites >1, Ki67 ≥40%, and absolute lymphocyte count less than the lower limit of normal. A multivariable model incorporating these formed the basis for a prognostic index for R/R TCL, in which patients are stratified into low-risk (0-1 risk factor), intermediate-risk (2-3 risk factors), or high-risk (≥4 risk factors) groups, which were associated with 3-year OS of 57.14%, 23.3%, and 7%, respectively. Patients received either a "novel" single agent (SA; 35%) or cytotoxic chemotherapy (CC; 60%) for their second-line treatment. Higher progression-free survival was observed with SA over CC for the entire cohort with a higher 3-year OS in AITL and ALK– ALCL. Among the SA, small-molecule inhibitors demonstrated OS advantage relative to CC in AITL. Our results highlight continued efficacy of novel drugs globally and the potential of a new prediction model in informing heterogeneous prognosis within the R/R population of MTCL and MNKCL.

15 September 2022 in Hematological Oncology
Verified
Journal Article
Closed access
CCCarlos Chiattone
Carlos Chiattone
MCMonica Civallero
Monica Civallero
TFThais Fischer
Thais Fischer
EMEliana Miranda
Eliana Miranda
MMMartina Manni
Martina Manni
GIGiorgio Inghirami
Giorgio Inghirami

29 June 2019 in Hematology, Transfusion and Cell Therapy
Verified
Journal Article
Open access
CPCamila Peña
Camila Peña
PBPablo Bolaños-Villegas
Pablo Bolaños-Villegas
MCMaría Elena Cabrera
María Elena Cabrera

1 April 2019 in Revista médica de Chile
Verified
Journal Article
Open access
PDF file
MCMaría Elena Cabrera C.
María Elena Cabrera C.
BLBárbara Puga L.
Bárbara Puga L.
VTVivianne Torres
Vivianne Torres
MSMauricio Salinas
Mauricio Salinas
Por este motivo el objetivo de los tratamientos de las últimas décadas ha sido reducir la intensidad del tratamiento en pacientes con enfermedad localizada, disminuyendo los campos y dosis de radioterapia (RT)2,3, excluirla completamente9,10 o disminuir el número de ciclos de quimioterapia (QT)3, y por otro lado, intensificar el tratamiento de primera línea en pacientes de alto riesgo con enfermedad avanzada5,11,12.

1 July 2019 in Revista médica de Chile
Verified
Journal Article
Open access
PDF file
JRJuvenal A. Ríos
Juvenal A. Ríos
EAElisa Alcalde
Elisa Alcalde
EREugenio Ramírez
Eugenio Ramírez
MCMyriam Campbell
Myriam Campbell
TLTomas P. Labbé
Tomas P. Labbé
MCMaría Elena Cabrera
María Elena Cabrera
The concept "Biobank" is relatively new in the scientific literature, and is not yet consensually defined, even for the World Health Organization (WHO). However, the use of human samples in biomedical research is a very old activity. The organized development of Biobanks in different places has grown in the last decade. The experience in different countries and continents has been diverse. In this special article we intend to summarize, organize and communicate to the national medical and scientific community, (i) the concept of Biobank, (ii) the international experience and a map of the Research Biobanks working in Chile, (iii) the basic biomedical and essential operational aspects to manage a Biobank for Research and (iv) the impact of a National Network of Biobanks implementation in the Chilean Health System. Ethical and regulatory aspects will not be included, given their intrinsic complexity, which should be discussed elsewhere.